UCB Secures EU Approval for Kygevvi as First-Ever Treatment for Ultra-Rare TK2 Deficiency
UCB (EBR: UCB) announced that the European Commission (EC) has granted marketing approval under exceptional...
Eli Lilly Restructures China Cardiometabolic Division Ahead of Foundayo Oral GLP-1 Launch
Eli Lilly and Company’s (NYSE: LLY) China unit announced a comprehensive organizational restructuring and key...
Huadong Medicine’s Semaglutide Biosimilar HDM1702 Enters NMPA Review for Weight Management Indication
Huadong Medicine Co., Ltd. (SHE: 000963) announced that the National Medical Products Administration (NMPA) has...
Lepu Medical Acquires Betagrin Rights from Bio-Thera in RMB 450 Million Cardiovascular Deal
Lepu Medical Technology (SHE: 300003), a leading Chinese provider of cardiovascular disease solutions, announced it...
Eli Lilly to Acquire CrossBridge Bio for Up to $300 Million to Bolster ADC Pipeline with Novel TROP2-Targeting Candidate
Eli Lilly and Company (NYSE: LLY) announced plans to acquire CrossBridge Bio, a Houston-based biotechnology...
Laekna Therapeutics Reports Breakthrough Phase III Results for LAE002 AKT Inhibitor in HR+/HER2- Breast Cancer
Laekna Therapeutics Shanghai Co., Ltd. (HKG: 2105) announced positive top-line results from a Phase III...
Johnson & Johnson Reports Strong Q1 2026 Sales Growth Despite Net Earnings Decline; Raises Full-Year Guidance
Johnson & Johnson (J&J, NYSE: JNJ) reported first-quarter 2026 results on April 14, 2026, showcasing...
Xuanzhu Biopharma Receives NMPA Approval for Phase III Trial of Anaprazole-Based Quadruple Therapy Against H. pylori
Xuanzhu Biopharmaceutical Co., Ltd. (HKG: 2575) announced it has received regulatory clearance from the National...
Shanghai Henlius Biotech Launches Phase I Trial for HLX05-N Cetuximab Biosimilar in Metastatic Colorectal Cancer
Shanghai Henlius Biotech, Inc. (HKG: 2696), a leading Chinese biopharmaceutical company, announced it has received...
Beijing Sinotau’s Prostate Cancer Diagnostic Agent XTR020 Receives NMPA Review Acceptance
Beijing Sinotau International Pharmaceutical Technology Co., Ltd., a specialized nuclear medicine enterprise, announced that the...
FDA Issues Draft Guidance for Genome Editing Therapy Safety Assessment Using Next-Generation Sequencing
The U.S. Food and Drug Administration (FDA) released draft guidance on Monday outlining standardized methods...
WinHealth Pharma Licenses World’s First Oral Arsenic Trioxide Arsenol for Mainland China APL Treatment
Hong Kong WinHealth Pharma Group has entered a licensing agreement with fellow Hong Kong firm...
Roche’s Elecsys NfL Test Gains CE Mark for Blood-Based Multiple Sclerosis Neuroinflammation Monitoring
Roche AG (SWX: ROG, OTCMKTS: RHHBY) announced on 13 April 2026 that its Elecsys Neurofilament...
Thermo Fisher’s PPD Secures 270M-Patient HealthVerity Dataset for AI-Driven Clinical Trial Optimization
Thermo Fisher Scientific (NYSE: TMO) announced a strategic data collaboration with HealthVerity, the leading real-world...
Ribo Life Science Advances World’s Leading FXI-Targeting siRNA Vortosiran into Phase IIb for AF Stroke Prevention
Suzhou Ribo Life Science Co., Ltd. (HKG: 6938) announced it has submitted an approval filing...
Daiichi Sankyo-Merck Ifinatamab Deruxtecan Granted FDA Priority Review for Extensive-Stage SCLC
Daiichi Sankyo (TYO: 4568) and Merck & Co., Inc. (MSD; NYSE: MRK) announced that the...
CureGene’s CG-0255 Receives NMPA Approval for Ischemic Stroke Trial – First Thiol-Based P2Y12 Inhibitor
Shanghai CureGene Pharmaceutical Co., Ltd announced it has received clinical trial approval from China’s National...
Grand Pharmaceutical’s SIR-Spheres Achieves Phase III Success in Unresectable HCC, Supporting China Expansion
Grand Pharmaceutical Group Co., Ltd. (HKG: 0512) announced that the Phase III clinical trial for...
China Resources and Roche Partner on Trastuzumab Emtansine Commercialization to Expand Breast Cancer ADC Access
China Resources Pharmaceutical Commercial Group announced in early March 2026 a strategic cooperation agreement with...
Zelgen’s Jaktinib Hits Primary Endpoint in Phase III Atopic Dermatitis Trial – Dual JAK/ACVR1 Inhibitor Expands Beyond Myelofusion
Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) announced that its Phase III clinical trial evaluating...